Term
|
Definition
| initiates local fibrinolysis by binding to fibrin in a thrombus and converts entrapped planminogen |
|
|
Term
|
Definition
| first recombinant tissue-type plasinogen activator |
|
|
Term
|
Definition
| angioedema, no allergic manifestations |
|
|
Term
|
Definition
|
|
Term
|
Definition
| fibrin specific, recombinant tissue-type plasminogen activator; seemed to have more rapid onset; allows bolus dosing |
|
|
Term
|
Definition
|
|
Term
|
Definition
| third generation thrombolic agent, single bolus administrations, decreased bleeding |
|
|
Term
|
Definition
| 20-30 minutes; 5-10 second bolus administration |
|
|
Term
|
Definition
| non-specific serine protease, single chain polypeptide derived from beta-hemolytic streptococcus cultures |
|
|
Term
|
Definition
|
|
Term
| adverse events of streptokinase |
|
Definition
| bleeding, antigenic, hypotension |
|
|
Term
|
Definition
| only FDA approved for acute PE, non-specific serine protease, major activator of fibrinolysis in the extavascular compartment |
|
|
Term
|
Definition
|
|
Term
|
Definition
| bleeding at local injection site, allergic reaction |
|
|
Term
| clinical use of fibrinolytic agents |
|
Definition
| acute MI (STEMI/NSTEMI), acute ischemic stroke, VTE (DVT and PE) |
|
|
Term
| r-tPA should be administered |
|
Definition
| within 4.5 hour window of onset of symptoms, no sings of hemorrhage per CT/MRI, blood pressure parameters met, two IV lines are placed and accurate body weight has been measured |
|
|
Term
| Intracerebral hemorrhage managment in t-PA overdose |
|
Definition
| stop t-PA and administer reversal agent as indicated (cryoprecipitate 10 units, platelets 6-8 units) |
|
|
Term
|
Definition
| is an extinct subspecies of the plains zebra that lived in South Africa. It was long thought to be a distinct species, but recent genetic studies have shown it to be the southernmost subspecies of the plains zebra |
|
|
Term
| ACCP suggests against giving fibrinolytics in ischemic stroke pts |
|
Definition
| between >3 and <4.5 hours |
|
|
Term
| ACCP suggests NOT using fibrinolytics in ischemic stroke pts |
|
Definition
|
|
Term
|
Definition
| FDA approved for ischemic stroke |
|
|
Term
|
Definition
| ASA (81mg daily), clopidogrel (75mg daily), dypiridamole/ASA (aggrenox 200/25 twice daily) |
|
|
